GSK3174998

DRUG5 trials

Conditions

Multiple MyelomaNeoplasmsRelapsed/Refractory Multiple Myeloma

Phase 1

GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)

CompletedNCT02528357

GlaxoSmithKlineNeoplasms

Start: 2015-09-11End: 2020-04-29Updated: 2021-05-18

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

CompletedNCT02723955

GlaxoSmithKlineNeoplasms

Start: 2016-06-23End: 2023-07-05Updated: 2024-12-27

Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

CompletedNCT03447314

GlaxoSmithKlineNeoplasms

Start: 2018-03-26End: 2022-03-11Updated: 2024-09-23

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

TerminatedNCT06160609

GlaxoSmithKlineRelapsed/Refractory Multiple Myeloma

Start: 2019-10-07End: 2023-01-09Updated: 2024-03-12

Phase 2

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Active, not recruitingNCT04126200

GlaxoSmithKlineMultiple Myeloma

Start: 2019-10-07End: 2027-03-11Updated: 2025-11-06

2024-02-1310 citations

P913: LOW-DOSE BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH NIROGACESTAT VS BELAMAF MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1/2 DREAMM-5 PLATFORM SUB-STUDY 3

HemaSphere2023-08-015 citations

Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade

Cancer Research Communications2023-07-1914 citations

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

Journal for ImmunoTherapy of Cancer2023-03-0157 citations

Manufacturing‐dependent change in biological activity of the <scp>TLR4</scp> agonist <scp>GSK1795091</scp> and implications for lipid A analog development

Clinical and Translational Science2022-09-1213 citations

Dostarlimab: A Review.

2022-07-2639 citations

Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.

Journal of Clinical Oncology2022-06-0125 citations

P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY

HemaSphere2022-06-01

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Blood2021-11-0512 citations

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

Cancer2021-07-27140 citations

Abstract CT033: Inducible T cell costimulatory (ICOS) receptor agonist, feladilimab (FE), alone and in combination (combo) with pembrolizumab (PE): Results from INDUCE-1 relapsed/refractory (R/R) melanoma expansion cohorts (EC)

Cancer Research2021-07-011 citations

Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).

Journal of Clinical Oncology2021-05-2031 citations

Belantamab Mafodotin in Combination with Novel Agents in Relapsed/refractory Multiple Myeloma: DREAMM-5 Study Design

Future Oncology2021-03-0833 citations

Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood2020-11-044 citations

Abstract CT150: A first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998) +/- pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1)

Cancer Research2020-08-1546 citations

Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology2020-05-2017 citations

INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors.

Journal of Clinical Oncology2020-05-2010 citations

First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1

Annals of Oncology2018-10-0111 citations

Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors

Cancer Research2017-07-017 citations

INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.

Journal of Clinical Oncology2017-05-2011 citations

3 more papers not shown

GSK3174998

Sponsors

Conditions

Phase 1

Phase 2

Related Papers